Telo Genomics Corp.: Telo Genomics' Multiple Myeloma Drug Resistance Study Results Have Been Selected for Presentation at the 2023 European Hematology Congress

Toronto, Ontario--(Newsfile Corp. - May 4, 2023) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") is pleased to announce that the abstract submitted to the European Hematology

Related Keywords

Toronto ,Ontario ,Canada ,United States ,American ,Canadian ,Kris Weinberg ,American Society For Clinical Oncology ,Telo Genomics Corp ,Mars Centre ,European Hematology Association ,Newsfile Corp ,Company Or Telo ,Mayo Clinic ,American Society ,Clinical Oncology ,European Hematology ,Monoclonal Gammopathy ,Unknown Significance ,South Tower ,Atelo ,Genomics ,Orp ,Multiple ,Myeloma ,Drug ,Resistance ,Study ,Results ,Wave ,Teen ,Elected ,Presentation ,023 ,European ,Hematology ,Congress ,